META

In the third quarter of 2025, MetaVia Inc. reported a net loss of $3.4 million, or $0.14 per share, based on approximately 24.4 million shares outstanding. This marks an improvement from a net loss of $5.7 million, or $0.55 per share, in the same quarter last year. Revenue was not disclosed. At the end of the quarter, the company had $14.3 million in cash, which is expected to fund operations into 2026. Research and development (R&D) expenses for the quarter were approximately $1.9 million, a significant decrease from $4.5 million in Q3 2024, primarily due to lower costs related to the development of its product candidates. During the quarter, MetaVia dosed the first patient in an 8-week cohort of its Phase 1 clinical trial for DA-1726, aimed at treating obesity. Top-line data from this trial is anticipated by the end of 2025. Additionally, the company is preparing for an end-of-Phase 2 meeting with the FDA in the first half of 2026 regarding vanoglipel, its treatment for metabolic dysfunction-associated steatohepatitis (MASH). MetaVia also formed a research collaboration with Syntekabio, Inc. to explore further disease targets and enhance the therapeutic profile of vanoglipel. The company presented new Phase 1 and pre-clinical data for DA-1726 at ObesityWeek® 2025, highlighting its potential benefits and safety profile.

In the third quarter of 2025, Meta Platforms, Inc. reported revenue of $51.24 billion, a 26% increase from $40.59 billion in the same quarter last year. However, net income fell to $2.71 billion, down 83% from $15.69 billion in Q3 2024, resulting in diluted earnings per share (EPS) of $1.05, compared to $6.03 a year prior. Additionally, the company faced a one-time, non-cash income tax charge of $15.93 billion due to the implementation of new tax legislation. Excluding this charge, net income would have been $18.64 billion, and the effective tax rate would have dropped to 14% instead of the reported 87%. Meanwhile, Meta's family of apps saw an increase in daily active users, reaching an average of 3.54 billion in September 2025, which is an 8% year-over-year growth. The company also experienced a 14% increase in ad impressions and a 10% rise in average ad prices, contributing to its revenue growth. On the operational front, Meta's cash, cash equivalents, and marketable securities amounted to $44.45 billion as of September 30, 2025. The company continues to invest heavily in research and development, with expenditures of $15.14 billion reported for the quarter, reflecting its commitment to enhancing its AI and immersive technology offerings.

In the second quarter of 2025, MetaVia Inc. reported a net loss of $4.0 million, or $0.26 per share, compared to a net loss of $10.1 million, or $1.85 per share, for the same period last year. The company had cash reserves of $17.6 million at the end of the quarter, which is expected to support operations into 2026. During this quarter, MetaVia dosed the first patient in the 8-week, 48 mg multiple ascending dose (MAD) cohort of its Phase 1 clinical trial for DA-1726, a treatment for obesity. Top-line data from this trial is anticipated in the fourth quarter of 2025. The company is also extending this cohort to evaluate longer-term efficacy and safety while exploring the maximum tolerated dose. Additionally, MetaVia announced a collaboration with Syntekabio to research new indications for DA-1241, a first-in-class oral GPR119 agonist. This partnership aims to utilize AI technology to screen over 1,700 validated protein targets, potentially enhancing DA-1241's therapeutic profile beyond its current focus on metabolic dysfunction-associated steatohepatitis (MASH). Research and development expenses for the second quarter were approximately $2.3 million, down from $8.1 million in the same quarter last year, primarily due to reduced spending on both DA-1241 and DA-1726 development. General and administrative expenses remained stable at about $2.0 million.